Industry
Biotechnology
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 8:12 pm
Portfolio Pulse from Chris Katje
April 19, 2024 | 4:28 pm
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 2:40 pm
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 10:15 am
Portfolio Pulse from Avi Kapoor
March 12, 2024 | 4:55 pm
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 4:49 pm
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 12:06 pm
Portfolio Pulse from Happy Mohamed
March 11, 2024 | 8:22 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 1:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.